Efficacy of thymosin α1 for sepsis: a systematic review and meta-analysis of randomized controlled trials
Wirksamkeit von Thymosin α1 bei Sepsis: systematische Übersicht und Metaanalyse randomisierter kontrollierter Studien
Frontiers in Cellular and Infection Microbiology · 03.09.2025 · 15
DOI: 10.3389/fcimb.2025.1673959 ↗Auf einen Blick
11 RCTs zeigen eine geringere 28-Tage-Mortalität unter Thymosin α1 als unter Kontrolle. In Untergruppen mit hoher Qualität und in multizentrischen Studien zeigte sich kein Mortalitätsvorteil.
Fragestellung
Wirkt Thymosin α1 bei Sepsis auf die 28-Tage-Mortalität?
Methode
Systematische Übersicht und Metaanalyse von RCTs; 3003 identifizierte Studien; TSA und HTE; Registrierung CRD42024628937.
Ergebnisse
11 RCTs mit 967 Patient:innen in der Tα1-Gruppe und 960 in der Kontrollgruppe. 28-Tage-Mortalität: OR 0,73 (95 %-KI 0,59–0,90; P = 0,003).
Einschränkungen
TSA deutet darauf hin, dass die Stichprobe unzureichend ist. HTE zeigte Heterogenität; Subgruppenbefunde teils niedrige Glaubwürdigkeit.
Schlussfolgerung der Autor:innen
Tα1 hat das Potenzial, die 28-Tage-Mortalität bei Sepsis zu senken; die Wirksamkeit unterscheidet sich jedoch zwischen Subgruppen.
Kernaussagen
- 28-Tage-Mortalität unter Tα1 geringer als unter Kontrolle
- Gesamtanalyse: OR 0,73 (95 %-KI 0,59–0,90)
- Nutzen in Subgruppen unterschiedlich; Stichprobe laut TSA zu klein
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Systematische Übersicht in der Zeitschrift Frontiers in Cellular and Infection Microbiology, online erschienen am 03.09.2025. Verfasst von Bin Gu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Critical Care Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China. Hauptthemen laut MEDLINE: Sepsis, Thymalfasin, Thymosin. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Sepsis
Abstract (Originalsprache)
Background
Despite advances in understanding sepsis pathophysiology and extensive research, few treatments effectively target its underlying immune dysfunction. Thymosin α1 (Tα1) shows promise as an immunomodulator, but its impact on sepsis remains unclear.
Methods
A search strategy was designed to include any prospective clinical studies using Tα1 for assessing 28-day mortality in patients with sepsis, excluding combination therapy studies. We conducted trial sequential analysis (TSA) to assess the robustness of meta-analyses findings. Heterogeneity of treatment effects (HTE) was conducted based on individual data from two multicenter randomized clinical trials (RCTs), with result credibility assessed through the instrument to assess the credibility of effect modification analyses (ICEMAN).
Results
Out of 3003 identified studies, 11 RCTs met the inclusion criteria (967 patients in Tα1 group and 960 patients in control group). The comprehensive meta-analysis demonstrated a significant reduction in 28-day mortality associated with Tα1 administration (OR 0.73, 95%CI: 0.59-0.90, P = 0.003). Nonetheless, analyses of high-quality (OR 0.82, 95%CI: 0.65-1.03, P = 0.09) and multi-center (OR 0.86, 95%CI: 0.68-1.08, P = 0.20) subgroups did not reveal a mortality benefit. The HTE analysis of multiple subgroups in two large RCTs (representing 75% of the total patients) showed heterogeneity. Potential benefits were noted in subgroups of cancer (moderate credibility), diabetes (low credibility), and coronary heart disease (low credibility). Furthermore, the trial sequential analysis (TSA) suggests that the current sample size is inadequate.
Conclusion
Tα1 has the potential to decrease 28-day mortality rates in patients with sepsis; however, it is crucial to recognize that its efficacy differs among various subgroups. These observations underscore the significance of personalized immunotherapy strategies in forthcoming clinical trials. Systematic review registration https://www.crd.york.ac.uk/prospero/ , identifier CRD42024628937.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Critical Care Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.
- Guangdong Clinical Research Center for Critical Care Medicine, Guangzhou, Guangdong, China.
Zitieren
APA
Gu, B., Zhou, Y., Nie, Y., Wang, L., Liang, L., Liao, Z., Wen, J., Guan, X., Chen, M., Wu, J., & Pei, F. (2025). Efficacy of thymosin α1 for sepsis: a systematic review and meta-analysis of randomized controlled trials. Frontiers in Cellular and Infection Microbiology, 15. https://doi.org/10.3389/fcimb.2025.1673959
Vancouver
Gu B, Zhou Y, Nie Y, Wang L, Liang L, Liao Z, et al. Efficacy of thymosin α1 for sepsis: a systematic review and meta-analysis of randomized controlled trials. Frontiers in Cellular and Infection Microbiology. 2025;15. doi:10.3389/fcimb.2025.1673959
BibTeX
@article{Gu2025,
author = {Gu, Bin and Zhou, Yu and Nie, Yao and Wang, Luhao and Liang, Liqun and Liao, Zihuai and Wen, Jingyi and Guan, Xiangdong and Chen, Minying and Wu, Jianfeng and Pei, Fei},
title = {Efficacy of thymosin α1 for sepsis: a systematic review and meta-analysis of randomized controlled trials},
journal = {Frontiers in Cellular and Infection Microbiology},
year = {2025},
volume = {15},
doi = {10.3389/fcimb.2025.1673959}
}
EUVIMED